» Articles » PMID: 33692194

Original Antigenic Sin: the Downside of Immunological Memory and Implications for COVID-19

Overview
Journal mSphere
Date 2021 Mar 11
PMID 33692194
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The concept of original antigenic sin (OAS) was put forth many years ago to explain how humoral memory responses generated against one set of antigens can affect the nature of antibody responses elicited to challenge infections or vaccinations containing a similar but not identical array of antigens. Here, we highlight the link between OAS and the germinal center reaction (GCR), a process unique to activated B cells undergoing somatic hypermutation and class switch recombination. It is the powerful response of activated memory B cells and the accompanying GCR that establish the foundations of OAS. We apply these concepts to the current COVID-19 pandemic and put forth several possible scenarios whereby OAS may result in either beneficial or harmful outcomes depending, hypothetically, on prior exposure to antigens shared between SARS-CoV-2 and seasonal human coronaviruses (hCoVs) that include betacoronaviruses (e.g., HCoV-OC43 and HCoV-HKU1) and alphacoronaviruses (e.g., HCoV-NL63 and HCoV-HKU1) (E. M. Anderson, E. C. Goodwin, A. Verma, C. P. Arevalo, et al., medRxiv, 2020, https://doi.org/10.1101/2020.11.06.20227215; S. M. Kissler, C. Tedijanto, E. Goldstein, Y. H. Grad, and M. Lipsitch, Science 368:860-868, 2020, https://doi.org/10.1126/science.abb5793).

Citing Articles

Receptor Binding Domain-Specific B Cell Memory Responses Among Individuals Vaccinated Against SARS-CoV-2.

Athavale A, Gaur A, Ahmed N, Subramaniam A, Dandotiya J, Raj S Vaccines (Basel). 2025; 12(12.

PMID: 39772064 PMC: 11680197. DOI: 10.3390/vaccines12121396.


Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination - kinetics of plasma antibodies, plasmablasts and memory B cells.

Wietschel K, Fechtner K, Antileo E, Abdurrahman G, Drechsler C, Makuvise M Front Immunol. 2024; 15:1382911.

PMID: 38807606 PMC: 11130424. DOI: 10.3389/fimmu.2024.1382911.


The "original antigenic sin" and its relevance for SARS-CoV-2 (COVID-19) vaccination.

Rijkers G, van Overveld F Clin Immunol Commun. 2024; 1:13-16.

PMID: 38620690 PMC: 8500682. DOI: 10.1016/j.clicom.2021.10.001.


Waning immunity and IgG4 responses following bivalent mRNA boosting.

Lasrado N, Collier A, Miller J, Hachmann N, Liu J, Anand T Sci Adv. 2024; 10(8):eadj9945.

PMID: 38394195 PMC: 10889350. DOI: 10.1126/sciadv.adj9945.


Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2.

Dulin H, Barre R, Xu D, Neal A, Vizcarra E, Chavez J J Virol. 2024; 98(2):e0157123.

PMID: 38206036 PMC: 10878257. DOI: 10.1128/jvi.01571-23.


References
1.
Patrick D, Petric M, Skowronski D, Guasparini R, Booth T, Krajden M . An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus. Can J Infect Dis Med Microbiol. 2008; 17(6):330-6. PMC: 2095096. DOI: 10.1155/2006/152612. View

2.
Flipse J, Diosa-Toro M, Hoornweg T, van de Pol D, Urcuqui-Inchima S, Smit J . Antibody-Dependent Enhancement of Dengue Virus Infection in Primary Human Macrophages; Balancing Higher Fusion against Antiviral Responses. Sci Rep. 2016; 6:29201. PMC: 4933910. DOI: 10.1038/srep29201. View

3.
Ng K, Faulkner N, Cornish G, Rosa A, Harvey R, Hussain S . Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020; 370(6522):1339-1343. PMC: 7857411. DOI: 10.1126/science.abe1107. View

4.
Stamper C, Wilson P . What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Is Affinity Maturation a Self-Defeating Process for Eliciting Broad Protection?. Cold Spring Harb Perspect Biol. 2017; 10(5). PMC: 5899041. DOI: 10.1101/cshperspect.a028803. View

5.
Lessler J, Riley S, Read J, Wang S, Zhu H, Smith G . Evidence for antigenic seniority in influenza A (H3N2) antibody responses in southern China. PLoS Pathog. 2012; 8(7):e1002802. PMC: 3400560. DOI: 10.1371/journal.ppat.1002802. View